| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
study archive
with methacholine |
Lung, respiratory function, baseline and methacholine-challenged (several doses). | QTL population | f | 7-8wks | 2005 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL, triglycerides, phospholipids. 4h fast, plasma. Baseline vs. high-fat diet (6wks). | inbred (15) | both | 6-14wks | 1999 |
|
|
protein activity assessment
with high-fat diet |
Phospholipid transfer protein activity. 4h fast. | inbred (15) | both | 6-14wks | 1999 |
|
|
metabolic panel
with high-fat high-sucrose diet |
Glucose, HOMA-IR, HOMA-B. | DO population | both | 4-26wks | 2018 |
|
|
hormone quantification
with high-fat high-sucrose diet |
Plasma insulin, adiponectin, leptin. Ex vivo insulin secretion. | DO population | both | 4-26wks | 2018 |
|
|
lipid profile
with high-fat high-sucrose diet |
Triglyceride. | DO population | both | 4-26wks | 2018 |
|
|
glucose tolerance
with high-fat high-sucrose diet |
Area under curve. | DO population | both | 4-26wks | 2018 |
|
|
monitoring system
with high-fat diet |
Oxygen consumption and respiratory exchange ratio (RER); activity. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
glucose tolerance
with high-fat diet |
Glucose post oral gavage: 0, 15, 30, 45, 60, 90, 120, 150, 180 min plus area under curve. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
hormone quantification
with high-fat diet |
Glucose post oral gavage: 0, 15, 30 min plus area under curve. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
body temperature
with high-fat diet |
In cold room: 0, 1, 2, 3, 4, 5, 6 h. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
treadmill endurance test
with high-fat diet |
Distance traveled. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
running wheel monitoring
with high-fat diet |
Distance traveled, speed. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
metabolic panel
with high-fat diet |
Enzymes, bile acid, proteins, creatinine, glucose, iron, lactate. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, LDL, free fatty acids, triglyceride. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
cell signaling molecule detection
with high-fat diet |
INF-gamma, interleukins, monocyte chemoattractant, macrophage inflammatory protein, T cell RANTES, TNF-alpha. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
monitoring system
with high-fat diet |
Oxygen consumption, carbon dioxide production, respiratory exchange rate (RER); activity. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
glucose tolerance
with high-fat diet |
Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
hormone quantification
with high-fat diet |
Insulin levels following glucose post oral gavage: 0, 15, 30 min. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
treadmill endurance test
with high-fat diet |
Distance traveled. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
metabolic panel
with high-fat diet |
Enzymes, creatinine, iron, lactate, urea. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, LDL, triglycerides, free fatty acids. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
study archive | Plasma lipids. Cholesterol, triglycerides. | QTL population | both | 12-14wks | 2013 |
|
|
study archive | Bone morphology and strength, insulin-like growth factor 1. | QTL population | f | 16wks | 2001 |
|
|
alcohol quantification
with ethanol |
Blood alcohol concentrations after ethanol injection over time, acute functional ethanol tolerance. | ILSXISS w/par (74) | both | 8-14wks | 2007 |
|
|
metabolic panel | Plasma enzymes, creatinine, glucose, urea, metabolic health score. | both | 8-20wks | 2021 | |
|
|
lipid profile | Cholesterol, non-esterified fatty acids, triglyceride. | both | 8-20wks | 2021 | |
|
|
biomarker quantification | TMAO, choline, phosphocholine, glycerophosphocholine, betaine, carnitine. | both | 8-20wks | 2021 | |
|
|
hormone quantification | Insulin, glucose:insulin ratio. | both | 8-20wks | 2021 | |
|
|
monitoring system | O2 consumption, CO2 production, RER, heat expenditure, activity. | both | 8-20wks | 2021 | |
|
|
intake monitoring | Food intake; energy intake; protein, carbohydrate, fat intake. | both | 8-20wks | 2021 | |
|
|
ventilator
with methacholine |
Airway resistance. Baseline vs. methacholine-challenged (several doses). | inbred (37) | both | 9-12wks | 2010 |
|
|
plethysmography
with methacholine |
Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 |
|
|
ventilator
with methacholine |
Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 |
|
|
metabolite quantification | Vitamin D concentration (serum). | inbred (18) | m | 11wks | 2011 |
|
|
study archive | Body, organ weights, litter size, abdominal fat, lipids, insulin, leptin. | QTL population | both | 3-6wks | 2009 |
|
|
ion transport assessment | Hematology red cell ion content, ion transport. | inbred (10) | both | 8wks | 2013 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
metabolic panel | Glucose (plasma). 4h fast. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
lipid profile | Cholesterol, HDL, triglycerides. 4h fast, plasma. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
metabolic panel | Clinical blood chemistry. 16h fast. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
metabolic panel | Clinical blood chemistry. 16h fast. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
study archive
with ethanol |
Sensitivity to ethanol. Baseline and ethanol. | QTL population | both | 9-34wks | 2012 |
|
|
glucose tolerance
with high-fat diet |
High-fat diet (17wks) vs. control. 0 to 120 min after 10% glucose i.p. 4h fast. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
|
lipid profile
with high-fat diet |
Cholesterol, triglycerides, free fatty acids. High-fat diet (17wks) vs. control. 4h fast, serum. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
|
hormone quantification
with high-fat diet |
Insulin, leptin. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
|
study archive
with ultraviolet light |
Immunosuppression of contact hypersensitivity after ultraviolet light exposure | QTL population | both | 9-30wks | 2000 |
|
|
hormone quantification
with Staphylococcus aureus |
Interleukin 6 levels (serum) after infection with Staphylococcus aureus. Kidney and peritoneal fluid. | inbred (13) | f | 8wks | 2012 |
|
|
drug and metabolite quantification
with diazepam |
Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. | inbred (15) | both | 6-7wks | 1998 |
|
|
body temperature
with diazepam |
Baseline vs. 30 min after diazepam injection (several doses). | inbred (15) | both | 6-7wks | 1998 |
|
|
alcohol quantification
with ethanol |
Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. | inbred (21) | both | 9-17wks | 2003 |
|
|
body weight
with haloperidol |
Baseline vs. after haloperidol 60d implant. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
drug and metabolite quantification
with haloperidol |
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | inbred w/CC7 (34) | m | 10wks | 2012 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | CC pre w/par (163) | m | 10wks | 2012 |
|
|
metabolic panel | Thyroxine (serum). | inbred w/CC7 (30) | both | 15-16wks | 2002 |
|
|
hormone quantification | Osteocalcin, insulin-like growth factor 1. | inbred w/CC7 (30) | both | 15-16wks | 2002 |
|
|
metabolic panel | Clinical blood chemistry (serum). 4h fast. | B6.PWD consomic w/par (25) | both | 11wks | 2011 |
|
|
study archive | Urinalysis. Creatinine, microalbumin, body weight. | QTL population | m | 8-10wks | 2008 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. Plasma. | inbred (8) | both | 12wks | 2007 |
|
|
metabolic panel | Clinical blood chemistry (plasma). Unknown fast. | inbred (8) | both | 12wks | 2007 |
|
|
glucose tolerance | 0 to 180 min after 20% glucose i.p. 16h fast. | inbred (4) | both | 12, 24, 52 wks | 2008 |
|
|
body temperature | Hourly readings in cold room. 6h test. | inbred (4) | both | 12wks | 2008 |
|
|
study archive | Colitis susceptibility, severity. Colon histopathology, body and spleen weight. | QTL population | both | 6wks | 2001 |
|
|
electroconvulsion test
with lamotrigine |
Electroconvulsive thresholds. Lamotrigine. 2 test sites. | inbred (16) | both | 6-11wks | 2000 |
|
|
metabolic panel | Glucose, glycerol. 16h fast. | inbred (5) | both | 10-11wks | 2020 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides, fatty acids. 16h fast, plasma. | inbred (5) | both | 10-11wks | 2020 |
|
|
monitoring system | Locomotor activity and energy metabolism. 21h test. | inbred w/CC8 (8) | both | 12-13wks | 2020 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | inbred w/CC8 (6) | both | 13-14wks | 2020 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
lipid profile | Cholesterol, triglycerides. No fast, plasma. | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
drug and metabolite quantification
with lithium |
Lithium concentration in brain tissue and blood serum after lithium (several doses). | inbred (11) | m | 7-8wks | 2011 |
|
|
drug and metabolite quantification
with nicotine |
Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. | inbred (8) | m | 8-12wks | 2011 |
|
|
RNA expression profiling
with West Nile virus |
Viral load and expression of Ifnb1 and Ifit1 in brain, kidney and spleen. | CC RIX (5) | m | 8-10wks | 2015 |
|
|
immune cell quantification | Baseline splenic T cell subsets. | CC RIX (104) | m | 8-10wks | 2021 |
|
|
histopathology
with ENU |
Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. | inbred (20) | both | 9wks; 12-64wks | 2006 |
|
|
genotype assessment
with Candida albicans |
C5 allele sufficiency or deficiency. | inbred (36) | f | 8-12wks | 2011 |
|
|
mineral quantification | concentrations of various minerals in milk | inbred (31) | f | 14-20wks | 2018 |
|
|
study archive | eQTL, urinary albumin excretion using microarray. | QTL population | m | 8-10wks | 2011 |
|
|
body weight
with isoniazid |
Body weight. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
organ weights
with isoniazid |
Body, liver, kidney weights. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
metabolic panel
with isoniazid |
Alanine transaminase. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
lipid profile
with isoniazid |
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
histopathology
with isoniazid |
Liver pathology scores. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
body weight
with DB289 |
DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
metabolic panel
with DB289 |
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
urinalysis
with DB289 |
Urine volume, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
organ weights
with DB289 |
Kidney and liver weights. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
biomarker quantification
with DB289 |
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
drug and metabolite quantification
with DB289 |
Kidney metabolite (DB75) concentration. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
health assessment
with radiation |
Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). | inbred (26) | both | 15-36wks | 2012 |
|
|
bronchoalveolar lavage assessment
with radiation |
Bronchoalveolar cell differential after exposure to radiation (18 Gy). | inbred (26) | both | 15-36wks | 2012 |
|
|
histopathology
with radiation |
Post exposure to radiation. | inbred (26) | both | 15-36wks | 2012 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. | HMDP (99) | m | 16wks | 2010 |
|
|
study archive
with high-fat diet |
Lipids, atherosclerosis lesions, parathyroid hormone after high-fat diet. | QTL population | f | 20wks | 2004 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | CC (18) | both | various | 2018 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | CC (18) | both | various | 2018 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, fatty acids. No fast, plasma. | CC (18) | both | various | 2018 |
|
|
hormone quantification | Insulin (plasma). | CC (18) | both | various | 2018 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | KOMP | both | 8-18wks | 2021 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | KOMP | both | 8-18wks | 2021 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, fatty acids. 4h fast, plasma. | KOMP | both | 8-18wks | 2021 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | KOMP | both | 8-18wks | 2021 |
|
|
hormone quantification | Insulin (plasma). | KOMP | both | 8-18wks | 2021 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | KOMP | both | 66-81wks | 2021 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | KOMP | both | 66-81wks | 2021 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
study archive | Characterization of high-muscle-mass mice. | QTL population | both | 3-10wks | 2011 |
|
|
study archive | Glucose, insulin, body and fat pad weights. | QTL population | m | 20-26wks | 2001 |
|
|
histopathology
with cadmium |
Cadmium-induced toxicity to liver, testis, trigeminal ganglia. | inbred (8) | m | 8wks | 2001 |
|
|
urinalysis | Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. | inbred (30) | both | 52, 78, 104 wks | 2008 |
|
|
metabolic panel | Glucose, bilirubin, aspartate transaminase (plasma). 4h fast. | B6.A consomic w/par (23) | both | 7-11wks | 2005 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, fatty acids. 4h fast, plasma. | B6.A consomic w/par (23) | both | 7-11wks | 2005 |
|
|
study archive | Type 1 diabetes development study. | QTL population | f | 14-40wks | 2009 |
|
|
study archive
with western diet |
Lipids, atherosclerosis lesion histopathology. High-fat, western-style diet. | QTL population | f | 12wks | 2008 |
|
|
running wheel monitoring | Distance, duration, speed. | inbred (41) | both | 8-9wks | 2010 |
|
|
body weight
with exercise |
Exercise (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
microscopy
with exercise |
Muscle fibers. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
muscle weights
with exercise |
Various muscles. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
organ weights
with exercise |
Heart weight. Cardiac ventricle weight. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
bone dimensions
with exercise |
Femur length. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
swim endurance test
with exercise |
Exercise vs. control, weekly for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
protein activity assessment
with exercise |
Muscle enzyme levels. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
study archive
with high-fat diet |
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. | QTL population | m | 16-18wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids (plasma), bile, liver weight, gallbladder and gallstone histopathology. | QTL population | m | 16-18wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids, gallbladder and gallstone histopathology after high-fat diet. | QTL population | m | 14-20wks | 2004 |
|
|
treadmill endurance test | Duration, distance, work. | inbred (34) | both | 8wks | 2012 |
|
|
body weight
with exercise |
Baseline vs. after exercise (access to running wheel). | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
MRI
with exercise |
Body composition (percent fat). Baseline vs. after exercise (access to running wheel). | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
intake monitoring
with exercise |
Caloric intake. Baseline vs. after exercise (access to running wheel). Metabolism, food intake. | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
running wheel monitoring
with exercise |
Distance, speed at days 1, 6, and 12. | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
study archive | Type 1 diabetes resistance. | QTL population | f | 8-40wks | 2003 |
|
|
body weight
with atenolol, isoproterenol |
Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
organ weights
with atenolol, isoproterenol |
Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
tail cuff
with atenolol, isoproterenol |
Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
ECG
with atenolol, isoproterenol |
Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
treadmill endurance test | Maximal distance is recorded when mouse fails to run. | CC (50) | f | 17-72wks | 2017 |
|
|
running wheel monitoring | Running wheel activity each day for 28 days. | CC (43) | f | 5-22wks | 2017 |
|
|
monitoring system
with exercise |
Locomotor activity, respiratory activity, body heat production, during 4 weeks of treadmill-based exercise training. 3 intensity cohorts. | CC (4) | both | 8-10wks | 2018 |
|
|
protein activity assessment | Acetylcholinesterase activity of cerebellum and dorsal and ventral hippocampus | inbred (20) | m | 8-12wks | 2021 |
|
|
metabolic panel
with high-fat high-sucrose diet |
Glucose, insulin, insulin resistance after 16wks of high-fat high-sucrose diet. 16h fast. | B6.A consomic w/par (24) | m | 5, 21 wks | 2015 |
|
|
lipid profile
with high-fat high-sucrose diet |
Cholesterol, triglycerides. 16h fast, plasma. Hepatic triglycerides. | B6.A consomic w/par (24) | m | 5, 21 wks | 2015 |
|
|
hormone quantification
with high-fat high-sucrose diet |
Insulin and insulin resistance after 16 wks of high-fat high-sucrose diet. Overnight fast. | inbred (2) | m | 21 wks | 2016 |
|
|
lipid profile
with high-fat high-sucrose diet |
Cholesterol and triglycerides. Overnight fast, plasma. Hepatic triglycerides. | inbred (2) | m | 21 wks | 2016 |
|
|
metabolic panel
with high-fat diet |
Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
hormone quantification
with high-fat diet |
Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
biomarker quantification | Temporal cortex amyloid level, age 6 and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
metabolic panel
with high-fat diet |
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. | inbred (44) | both | 15-19wks | 2000 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. | inbred w/CC7 (43) | both | 7-9wks, 24-27wks | 2002 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. | obesity mutants (8) | both | 15-19wks | 2000 |
|
|
metabolic panel
with high-fat diet |
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. | obesity mutants (8) | both | 15-19wks | 2000 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. | inbred w/CC7 (43) | both | 10wks | 2002 |
|
|
metabolic panel | Glucose (blood). Before and after 16h fast. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
metabolic panel | Glucose (blood). Before and after 16h fast. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
coagulation test | Fibrinogen. | inbred w/CC7 (43) | both | 10wks | 2001 |
|
|
study archive
with high-fat diet |
Cholesterol (plasma) after high-fat diet (several timepoints). | QTL population | f | 6-26wks | 2002 |
|
|
hormone quantification | Corticosterone (serum). | inbred (32) | m | 7-9wks | 2007 |
|
|
study archive | Body weight (several ages), fat mass, body mass index, fat pad weights. | QTL population | m | 4-24wks | 2000 |
|
|
study archive | Type 1 diabetes onset. | QTL population | f | 12-40wks | 2005 |
|
|
running wheel monitoring
with exercise |
Locomotor activity. Exercise wheel group vs. control group. Distance per day. | inbred (12) | both | 8-15wks | 2010 |
|
|
body weight
with exercise |
Exercise wheel group vs. control group. | inbred (12) | both | 8-15wks | 2010 |
|
|
microscopy
with exercise |
Examination of hippocampus dentate gyrus. Exercise wheel group vs. control group. | inbred (12) | both | 8-15wks | 2010 |
|
|
proteomic profiling | Hair proteomics analysis. Spectral counts for 46 specific proteins. | inbred (11) | both | 10-19wks | 2012 |
|
|
study archive
with macronutrient diet option |
Caloric intake, glucose, body and fat pad weights. Macronutrient diet option. | QTL population | m | 8-13wks | 2002 |
|
|
neurotransmitter quantification | Neurotransmitters. Molecular measures. | inbred (15) | m | 7-9wks | 2003 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred RBRC (56) | both | 8, 12 wks | 2008 |
|
|
lipid profile | Cholesterol, HDL, triglycerides. 4h fast, plasma. | inbred RBRC (56) | both | 8, 12 wks | 2008 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | wild-derived RBRC (33) | both | 8, 12 wks | 2008 |
|
|
lipid profile | Cholesterol, HDL, triglycerides. 4h fast, plasma. | wild-derived RBRC (33) | both | 8, 12 wks | 2008 |
|
|
metabolic panel
with trichloroethylene |
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum). Baseline and trichloroethylene-exposed (several timepoints). No fast. | inbred (17) | m | 7wks | 2010 |
|
|
drug and metabolite quantification
with trichloroethylene |
Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. | inbred (17) | m | 7wks | 2010 |
|
|
metabolic panel
with high-fat diet and ethanol |
Alanine transaminase (serum) after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
alcohol quantification
with high-fat diet and ethanol |
Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
metabolite quantification
with high-fat diet and ethanol |
Homocysteine concentration after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
lipid profile
with high-fat diet and ethanol |
Hepatic triglycerides after 4wk regimen of ethanol and high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
organ weights
with trichloroethylene |
Liver, kidney weights. Trichloroethylene-exposed vs. control. | inbred (7) | m | 6-7wks | 2014 |
|
|
metabolic panel
with trichloroethylene |
Blood urea nitrogen (serum). Trichloroethylene-exposed vs. control. | inbred (7) | m | 6-7wks | 2014 |
|
|
drug and metabolite quantification
with trichloroethylene |
Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. | inbred (7) | m | 6-7wks | 2014 |
|
|
RNA expression profiling
with trichloroethylene |
Trichloroethylene effect on mRNA gene expression in liver and kidney, relative to controls. | inbred (7) | m | 6-7wks | 2014 |
|
|
histopathology
with trichloroethylene |
Kidney histopathology evaluation after trichloroethylene exposure, relative to controls. | inbred (7) | m | 6-7wks | 2014 |
|
|
health assessment | Post-injury wound healing. Ear cartilage and articular cartilage. | LGXSM w/par (15) | both | 6-7wks | 2012 |
|
|
histopathology | Post-injury wound healing. Articular cartilage at 12wks and 16wks post-injury. | LGXSM w/par (15) | both | 6-7wks | 2012 |
|
|
body temperature
with various diets |
Temperature before and after stress. Comparison of 4 diets. | CC RIX (18) | f | 8-9 wks | 2018 |
|
|
hormone quantification
with various diets |
Serum corticosterone at baseline and 10 mins after stress. Comparison of 4 diets. | CC RIX (18) | f | 8-9 wks | 2018 |
|
|
glucose tolerance | 0 to 120 min after 10% glucose i.p. 5h fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
insulin tolerance | 0 to 120 min after insulin i.p. 5h fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
lipid profile | Cholesterol, triglycerides, free fatty acids, phospholipids. 5h fast, plasma. Hepatic triglycerides. | inbred (11) | both | 8-10wks | 2005 |
|
|
metabolic panel | Glucose, beta-hydroxybutyrate (plasma). No fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
hormone quantification | Insulin level, 30 min post-injection in glucose tolerance test. 10% glucose. 5h fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
glucose tolerance
with high-fat diet |
Plasma glucose levels at 0, 30, 60 min post oral gavage of Ensure Plus, overday fast. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
|
bronchoalveolar lavage assessment
with ovalbumin |
Lung inflammatory changes. Ovalbumin vs. control. | inbred (8) | m | 6-8wks | 2001 |
|
|
monitoring system | Locomotor activity and energy metabolism. 24h test. | inbred (16) | both | 7-9wks | 2001 |
|
|
study archive | Urinalysis. Creatinine, microalbumin, body weight. | QTL population | m | 10wks | 2007 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, triglycerides, fatty acids. High-fat diet (4wks) vs. control. 5h fast, serum. | inbred (10) | both | 10-13wks | 2008 |
|
|
metabolic panel
with high-fat diet |
Clinical blood chemistry measures (serum). High-fat diet (4wks) vs. control. | inbred (10) | both | 10-13wks | 2008 |
|
|
study archive | Open field test, forced swim test, defensive burying task. | QTL population | both | 11-17wks | 2004 |
|
|
study archive | Lipids. Cholesterol, triglycerides, body weight. | QTL population | both | 8-10wks | 2006 |
|
|
study archive
with high-fat diet |
Lipids (plasma). Cholesterol, triglycerides, aortic lesions, body mass index. | QTL population | f | 14wks | 2009 |
|
|
RNA expression profiling
with selenium |
Selenium regulation of selenoprotein enzyme activity and transcripts. | inbred w/CC8 (8) | m | 3-14wks | 2018 |
|
|
coagulation test | Fibrinogen, anti-thrombin III, factor VIII | B6.PWD consomic w/par (28) | both | 9wks | 2006 |
|
|
metabolic panel | Glucose, bilirubin, blood urea nitrogen, aspartate transaminase (plasma). 4h fast. | B6.PWD consomic w/par (28) | both | 9wks | 2006 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | B6.PWD consomic w/par (28) | both | 9wks | 2006 |
|
|
metabolic panel
with acetaminophen |
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
biomarker quantification
with acetaminophen |
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
organ weights
with acetaminophen |
Liver weight after acetaminophen (several doses) vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolic panel
with acetaminophen |
Alanine transaminase (serum). Acetaminophen (several doses) vs. control. | inbred (5) | m | 6-8wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Glutathione. | inbred (5) | m | 6-8wks | 2005 |
|
|
drug and metabolite quantification
with acetaminophen |
Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). | inbred (5) | m | 6-8wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis, injury after acetaminophen vs. control. 18h fast. | inbred (5) | m | 6-8wks | 2005 |
|
|
biomarker quantification | Fibronectin. | inbred (25) | both | 9wks | 2007 |
|
|
metabolic panel | Ionized and total blood calcium, blood pH. | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
hormone quantification | Corticosterone levels (plasma). Baseline vs. after stress (30 min in restraining cage). | inbred (16) | m | 6-8wks | 1993 |
|
|
mineral quantification | Liver mineral levels. Iron, copper, zinc. Iron homeostasis. | inbred (18) | both | 8wks | 2010 |
|
|
transferrin quantification | Diferric transferrin (plasma). | inbred (18) | both | 8wks | 2010 |
|
|
study archive
with high-fat diet |
Lipids (plasma). Cholesterol, inducibility, triglycerides, atherosclerosis lesions. | QTL population | f | 10-23wks | 2003 |
|
|
drug and metabolite quantification
with fluoxetine |
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. | inbred (30) | m | 9-11wks | 2011 |
|
|
biomarker quantification
with fluoxetine |
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. | inbred (30) | m | 10-11wks | 2011 |
|
|
immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib |
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. | inbred w/CC7 (36) | m | 10wks | 2015 |
|
|
study archive
with high-fat diet |
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. | QTL population | both | 6-16wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. | QTL population | both | 2005 | |
|
|
inclined screen test | Latency to move all four paws. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
open field test | Locomotor activity, anxiety, stereotypy. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
behavior observation | Vacuous chewing, tongue protrusion, jaw tremor. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
drug and metabolite quantification | Plasma haloperidol concentration. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
body weight
with arsenic |
Baseline, then after iAs exposure for 26 wks | DO population | m | 4-34 wks | 2022 |
|
|
intake monitoring
with arsenic |
Food and water consumption, at baseline then at 1 to 4 wk intervals after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
MRI
with arsenic |
Fat and lean tissue mass at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
urinalysis
with arsenic |
Urine volume at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolic panel
with arsenic |
Blood glucose following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
hormone quantification
with arsenic |
Blood insulin following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolite quantification
with arsenic |
iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) | DO population | m | 4-34 wks | 2022 |
|
|
hormone quantification | Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
metabolic panel | Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
lipid profile | Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
study archive
with western diet |
Atherosclerosis and glucose homeostasis. Lesions, lipids, glucose, insulin. High-fat, western-style diet. | QTL population | f | <6-18wks | 2012 |
|
|
monitoring system | Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |